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ABSTRACT
Monoclonal antibodies (MAbs) 123C3 and I23A8 generated against a 
membrane preparation of a small cell lung carcinoma (SCLC) specimen 
recognize not only SCLC and bronchial carcinoids but also a significant 
portion of non-small cell lung carcinomas (non-SCLC) of various histo­
logical types. Together with 13 other monoclonal antibodies, which show 
preference for SCLC, they have been ranked as SCLC cluster 1 (SC-I) 
Mabs.
In this study we show that SC-1 MAbs are directed against a restricted 
number of epitopes, and that SC-1 MAbs and a polyclonal antiserum 
directed against the neural cell adhesion molecule (NCAM) recognize 
identical glycoproteins, indicating that SC-1 antigens are closely related 
to or identical with NCAM* Long polysialic acid units composed of a- 
(2,8)-linked /V-acetylneuraminic acid units, which in mammals are found 
exclusively on NCAM, were present on SC-1 antigens in SCLC. This 
provides further evidence that SC-1 MAbs recognize NCAM, The SC-1 
antigens in the SCLC cell line H69 were present in two forms, NCAM- 
containing a-(2,8)-poIysiaIic acid units identified by antiserum 735, the 
NCAM-H form, and the less sialylated NCAM-L form. The NCAM-H 
form consisted of diffusely migrating sialoglycoproteins with a molecular 
weight of 200,000-250,000, which resolved after neuraminidase treat­
ment into two proteins with molecular weights of 140,000 and 180,000.
Since the NCAM-H form is expressed in the lung tumor type with a 
poor prognosis, our results suggest that NCAM might be implicated in 
the invasive behavior of these NCAM-positive lung tumors.
INTRODUCTION
Human small cell lung carcinoma shows neuroendocrine 
features such as the production of peptide hormones and the 
presence of marker enzymes, and of neurosecretory granules 
(1, 2). SCLC4 accounts for about 25% of the bronchial malig­
nancies and has an extremely poor prognosis. Because of dif­
ferences in treatment and prognosis between SCLC and non- 
SCLC, a clear distinction between these two lung tumor types 
is of great clinical importance. For that purpose, a number of 
MAbs against SCLC have been produced (3-5), including 
MAbs 123C3 and 123A8 generated in the Netherlands Cancer 
Institute (3). The antigens recognized by these SCLC-MAbs 
have not yet been defined. The tissue distribution patterns of 
these MAbs were compared at the First International Work­
shop on SCLC and the MAbs were ranked accordingly (6, 7). 
Our MAbs 123C3 and 123A8 were, among others, character*-
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ized as SCLC preferent and were classified in SC-1. The MAbs 
recognized also other tumor types with neuroendocrine fea­
tures, such as neuroblastoma, glioma, and melanoma. The 
tissue distribution pattern of the SC-1 MAbs in normal human 
adult, and especially in embryonic tissues, showed similarities 
with the tissue distribution pattern of the NCAM (8).5 This 
finding prompted us to investigate a possible relationship be­
tween SC-1 antigens and cellular adhesion molecules. Here we 
present data demonstrating that the SC-1 antigens are related 
to or identical to NCAM. NCAM is a family of cell surface 
sialoglycoproteins involved in homotypic and heterotypic odi­
celi binding via a homophilic binding mechanism. Various 
NCAM isoforms have been described, and it has been found 
that these are generated by alternative RNA splicing from a 
single copy gene (9-11). Additional heterogeneity is provided 
by differential glycosylation (12). Expression of NCAM iso­
forms is regulated in a developmental stage and tissue type- 
specific manner. NCAM isoforms are heavily sialylated in 
embryonal mouse brain and have a molecular weight of 
200,000-250,000. Less sialylated NCAM proteins appear dur­
ing embryonal development, and as a result of this, three 
discrete NCAM proteins with molecular weights of 120,000, 
140,000, and 180,000 become apparent in adult mouse brain
(13)\It is assumed that variation in NCAM isoforms influences 
the functional properties of NCAM molecules (13-16). Becausc 
of its role as an adhesion molecule, NCAM, and in particular 
NCAM isoform modifications in tumor versus normal tissues, 
might affect invasiveness and thereby influence the malignan! 
behavior of tumor cells.
MATERIALS AND METHODS
Cell Lines, Antibodies. Neuroblastoma cell line CHP-212 was kindly 
provided by Dr. H. Schlesinger, the University of Pennsylvania, Phila­
delphia, PA (17). SCLC cell line H69 (18) was a generous gift of Dr. 
D. Carney, National Cancer Institute, Bethesda, MD. Cell lines were 
maintained in Dulbecco’s modified Eagle’s medium, supplemented wilh 
10% fetal calf serum and antibiotics. SC-1 MAbs, used in our study 
(19-22), are depicted in Table 1. MAbs 1, 2 and MAbs 3, 4, 5 (Table 
1) were raised in the Netherlands Cancer Institute against a membrane 
fraction of a SCLC tumor specimen (3) and neuroblastoma cell line 
CHP-212, respectively. A rabbit antiserum directed against the human 
NCAM and MAb 735, directed against homopolymers o f  a-(2,8)-A' 
acetyineuraminic acid, were generated by us [respectively, E, B. (23) 
and D. B-S. (24)]. MAbs 661G10 and 67D11 were raised in the Neth­
erlands Cancer Institute and are directed against the transferrin receptor 
(25) and MAM-3 (26), respectively.
Immunoinhibition Assay. Cells (IO6; H69 or CHP-212) were incu­
bated with excess unlabeled first antibody in PBS-0.2% BSA, for 1 li 
at room temperature. Subsequently, the cells were incubated with a 
second ,25I-Iabeled antibody for 15 min. Unbound antibody was washed 
away with PBS-0.2% BSA, and bound radioactive labeled antibody was 
measured in a gamma counter. Binding of the labeled antibodies in the
5 A. A. Van der Gugten and P. Hagcman, manuscript in preparation.
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1. 123C3 IgGl 145,000, 185,000 3
2. 123A8 IgGl 145,000,185,000 3
3. NKI-nbl-1 IgGl 145,000, 185,000
4. NKI-nbl-2 IgGl 145,000, 185,000
5. NKI-nbl-3 IgG2 145,000, 185,000
6. MOC-1 IgGl 125,000 19
7. MOC-21 IgG2a 25,000 19
8. MOC-32 IgM 40,000 19
9. NE-25 IgGl 25,000, 150,000 20
10. NE-150 IgGl 150,000 20
11. NCC-LU-243 IgG2a 145,000 21
12. NCC-LU-246 IgGl 145,000 21
13. S-L ì 1-14 IgG2a Glycoprotein 22
presence of normal mouse serum provided the 100% binding value. 
The binding values were corrected for the percentage inhibition of 
binding of a nonspecific 125I-labeled MAb, for which MAb 66IG10 
directed against the transferrin receptor (25) was used.
Immunoprécipitation Procedures, Cells were surface labeled with ,25I- 
iodide and lactoperoxidase and were subsequently lysed in 25 niM Tris- 
100 mM NaCl-2 mM EDTA pH 8.3-1% Nonidet P-40, in the presence 
of protease inhibitors: phenylmethylsulfonyl fluoride, trypsin inhibitor, 
and aprotinin (lysis buffer). Cell lysates were precleared with protein 
A-Sepharose CL-4B (Pharmacia, Woerden, The Netherlands) and nor­
mal mouse serum. Immunoprécipitations were performed with MAbs 
or polyclonal antisera, and protein A-Sepharose CL-4B, The specific 
immunoprecipitates were washed four times in lysis buffer and twice in 
lysis buffer without Nonidet P-40. Immunoprecipitated material was 
dissolved in 30 ßl of 0.6 mM Tris-20% glycerol-4% SDS-0.05% bro- 
mophenol blue 10% (v/v) ß-mercaptoethanol, pH 6 ,8 . After the samples 
were boiled for 5 min or were kept at 63°C for 10 min (see Fig. 4), the 
samples were clarified by centrifugation (5 min, 10,000 X g) and 
analyzed by SDS-polyacrylamide gel electrophoresis according to the 
method of Laemmli (27). High molecular weight markers from Bio- 
Rad (Utrecht, The Netherlands) were used as reference. After electro­
phoresis, gels were fixed and stained in methanohacetic acid:water 
(5:1:5) containing Coomassie Brilliant Blue and destained in metha- 
nokacetic acid:water (75:200:725). The gels were dried and exposed to 
Kodak X-Omat AR films at —70,5C.
Western Blotting. NKI-nbl-3 immunoprecipitates (see “Immunopré­
cipitation Procedures”) were incubated for 10 min at 63°C instead of 
being boiled for 5 min, separated on a 5% SDS-polyacrylamide gel 
under reducing conditions, and subsequently transferred to a nitrocel­
lulose filter in Tris/glycine buffer, pH 8.5, at 4°C. Immunostaining was 
carried out with MAbs (1/100 ascites dilution) in PBS-1% BSA-0,2% 
Tween 20 using the Protoblot lmmunoscreening System (Promega, 
Leiden, The Netherlands).
Enzyme Treatments. For neuraminidase treatment, immunoprecipi­
tates (see “Immunoprécipitation Procedures”) were suspended in 50 
mM sodium acetate- 1 mM CaCl2, pH 5,5, and incubated with 50 
milliunits of neuraminidase from Vibrio cholerae (Calbiochem, San 
Diego, CA) for 4 hat 37’C.
Pro tease Staphylococcus aureus V8 digestions were performed as 
described by Cleveland et al. (28). Briefly, Mr 90,000 or 145,000 
proteins from immunoprecipitates with 66IG10 or NKI-nbl-3 and 
NCAM antisera, respectively, were excised from the gel and subse­
quently incubated with various amounts of protease during 30 min at 
2TC. Digested peptides were separated on a 15% Laemmli slab gel.
RESULTS
Immunoinhibition Studies. We compared various SC-1 MAbs 
in an immunoinhibition assay in which the binding of a radio- 
actively labeled MAb is examined in the presence of competing 
antiserum. As test cells, we used SCLC cell line H69 or neuro­
blastoma cell line CHP-212. Both cell lines were positive for 
SC-1 MAbs in an immunofluorescence assay. Inhibition exper­
iments with ,25I-labeled antibodies 123C3, 123A8, and NKI-
nbl-3 and unlabeled MAbs 123C3, 123A8, NKI-nbl-3, NCC- 
LU-243, and MOC-32 showed complete inhibition (Table 2), 
indicating that this group of MAbs binds to identical or spatially 
close epitopes. Similarly, MAbs NKI-nbl-1, NKI-nbl-2, NCC- 
LU-246, NE-25, NE-150, S-L 11-14, MOC-1, and MOC-21 
share the same or closely adjacent epitopes (Table 2). These 
two groups of MAbs inhibited each other partially in their 
binding (Table 2). This is probably due to steric hindrance and 
therefore suggests that these two antigenic determinants are 
located close to each other on the same polypeptide.
Biochemical Characterization of the SC-1 Antigen. The var­
ious SC-1 MAbs were compared in immunoprécipitation stud­
ies, using cell surface 125I-labeled CHP-212 cells. MAbs NKI- 
nbl-3 and NCC-LU-243 precipitated two proteins with molec­
ular weights of 145,000 and 185,000 (Fig. 1, Lanes 3 and 11). 
After longer film exposure time, both proteins were also iden­
tified in immunoprecipitates of the other SC-1 MAbs. All SC- 
1 MAbs recognized the same protein doublet, the amount of 
antigen precipitated however, varied among the different SC-1 
MAbs. This is probably due to differences in the affinity of the 
MAbs used. Mab MOC-21 precipitated a third antigen with a
Table 2 Immunocompctition with the various SC-1 MAbs
The binding of a radiolabeled MAb (second MAb-l25l) is determined in the 
presence of excess competitive antiserum (first MAb) on live CHP212 or H69 
cells. Data given are mean values of three experiments, values differed less than 
10%.
First MAb








123C3 4 3 97 100 100
123A8 4 3 1 98 85 100
NKI-nbl-3 2 2 1 81 75 100
NCC-LU-243 4 1 1 94 93 100
MOC-32 3 1 1 72 85 100
NKI-nbl-2 56 54 57 1 1 100
NKI-nbl-1 57 64 75 2 1 100
NCC-LU-246 72 77 78 1 1 100
NE-25 66 69 76 1 1 100
NE-150 68 65 79 2 1 100
S-L 11-14 62 62 60 5 6 100
MOC-1 58 59 58 5 5 100
MOC-21 55 61 71 8 8 100
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Fig, 1. Characterization of SC-1 antigens in CHP-212 cclls. Immunoprecipi* 
tates of 125I-cell surface-labeled CHP-212 cells and MAbs NKI-nbl-1 (Lane /), 
NKI-nbl-2 (Lane 2), NKI-nbl-3 (Lane 3), 123C3 (Lane 4), 123A8 (Lane 5), NE- 
25 CLane <5), NE-150 (Lane 7), NCC-LU-246 (Lane S), MOC-1 (Lane 9), MOC- 
21 (Lane 10), NCC-LU-243 (Lane U ), S-L 11-14 (Lane 12), 66IG1Û (Lane 13), 
and 67DU (Lane 14).
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molecular weight of 165,000 (Fig. 1, Lane 10); the nature of 
this third band still remains to be studied. The control MAb, 
66IG10, precipitated a Mr 90,000 protein (Fig. 1, Lane 75), as 
was expected (25).
Mab 123C3 Recognizes Human NCAM. The tissue distribu­
tion pattern of SC-1 MAbs in human adult and fetal tissues 
resembled the pattern of the NCAM, (8).5 This finding 
prompted us to investigate a possible relationship between SC- 
1 antigens and NCAM. We therefore used a polyclonal NCAM 
antiserum generated against rat brain NCAM, which also rec­
ognizes human NCAM (23), and studied the relationship be­
tween NCAM and SC-1 antigens in three ways: by immunoin­
hibition; by immunoprécipitation and by S . aureus V8 protease 
digestion studies.
Immunoinhibition experiments with NCAM antiserum and 
I25I-SC~1 MAbs showed complete inhibition of MAb 123C3, 
123A8, and NKI-nbl-3 and partial inhibition of MAbs NKI- 
nbl-1 and -2 (Table 3), indicating that the investigated SC-1 
MAbs are directed to cell surface proteins that are immunolog- 
ically related to NCAM. The partial inhibition of MAbs NKI- 
nbl-1 and ~2 is probably due to an underrepresentation in the 
polyclonal NCAM antiserum of antibodies recognizing this 
determinant.
In immunoprécipitation studies using l25I-labeled CHP-212 
or H69 cells, the NCAM antiserum precipitated two proteins, 
one major protein (Mr 145,000) and one Mr 185,000 protein 
(Fig. 2, Lane 5), comparable to the proteins precipitated by SC- 
1 MAbs (Fig. 2, Lane 1-4). The molecular weight of the Mr 
145,000 and 185,000 proteins differed only slightly under non­
reducing conditions when compared to reducing conditions (a 
Mr 125,000/180,000 protein doublet; data not shown), This is 
probably due to intrachain disulfide bridges, which have been 
described for chicken NCAM (9). S . aureus V8 protease diges­
tion of the M r 145,000 protein preparations, which were im- 
munoprecipitated from CHP-212 cells by MAb NKI-nbl-3 (Fig. 
2¡Á) and by NCAM antiserum (Fig. 32?), showed a similar 
peptide fragment pattern, suggesting that SC-1 MAbs and 
NCAM antiserum indeed recognize identical proteins. The 
peptide pattern of the MT 90,000 transferrin receptor protein, 
which was used as control, showed a quite different pattern
(Fig. 3C).
a-(2,8)-Polysialic Acid Units on NCAM Proteins in SCLC. 
Another NCAM-specific antiserum used in our study is MAb 
735. This MAb recognizes a-(258)-linked PSA units with a 
chain length of at least 8 residues (29). In mammals, this type 
of PSA has thus far been found only on particular forms of 
NCAM (8, 29). To determine whether these a-(2,8)-PSA units 
are also present on NCAM proteins in SCLC, we analyzed 
Western blots of H69 cell preparations with MAb 735. For that 
purpose, NCAM proteins were at first immunoprecipitated with 
MAb NKI-nbl-3 from H69 cells, separated by SDS-polyacryl- 
amide gel electrophoresis, and subsequently transferred to a
Table 3 Jmmunocompetition with a polyclonal antiserum directed against human
NCAM
The binding of a radiolabeled MAb (second MAb-12sI) is determined in the 
presence of NCAM antiserum on live CHP212 cells. Data given are mean values 
of two experiments, values differed less than 5%.
First
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Fig. 2, Identification of antigens recognized by SC-1 MAbs and NCAM 
antiserum in CHP-212 cells. Immunoprecipitates of l25I-cell surface-labeled CHP- 
212 cells with MAb 123C3 (Lane J), NKI-nbl-1 (Lane 2), NKI-nbl-2 (Lane 3), 
NKI-nbl-3 (Lane 4), polyclonal rabbit antiserum directed against N-CAM (Lane 
5), normal rabbit serum {Lane 6), and control mouse IgG (Lanes 7 and 8).
A B c
1 2 3  1 2 3  1 2 3
Fig. 3. S. aureus V8 peptide maps of the Mt 145,000 antigens immunoprecip­
itated from CHP212 cells with MAbs NKI-nbl-3 (A ), NCAM antiserum (5), and 
a control antigen, the Mt 90,000 transferrin receptor, immunoprecipitated by 
MAb 66IG10 (C). Polypeptides were digested with various amounts of S. aureus 
V8 protease. Lane 1, 0 ^g; Lane 2, 5 /¿g; Lane 5, 25 ^g.
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nitrocellulose filter. Immunostaining was then carried out with 
MAbs NKI-nbl-3 or 735. We analyzed the preparations under 
conditions at which the a-(2,8)-PSA-rich NCAM forms are 
observed, i.e., dissolving the immunoprecipitates at 63°C for 
10 min, instead of boiling the samples for 5 min as is usually 
done. The latter procedure removes the a-(2,8)-PSA units from 
NCAM proteins (30). MAb NKI-nbl-3 immunostained the 
NCAM proteins with molecular weights of 145,000 and 
185,000, as was to be expected (Fig. 4A, Lane 2). After treat­
ment with V. cholerae neuraminidase, which removes all neu­
raminic acid, the SC-l MAbs recognized two antigens with 
molecular weights of 140,000 and 180,000 (Fig. 4A, Lane 1). 
A diffuse staining remained at the high molecular weight region 
in the lane of the untreated NCAM preparation (Fig. 4A, Lane 
2) but disappeared after neuraminidase treatment (Fig. 4A, Lane 
1). The diffusely migrating proteins in the high molecular 
weight region therefore represent the NCAM-H proteins. MAb 
735 did not recognize the neuraminidase-treated NCAM pro­
teins, as was to be expected (Fig. 4B, Lane 1) but identified 
only the NCAM-H proteins in the Mr 200,000-250,000 range 
of the gel (Fig. 4B, Lane 2). The unmodified Mr 145,000 and
185.000 proteins were not recognized by MAb 735 and there­
fore represent the NCAM-L proteins that possess no or only 
very short homopolymers of a-(2,8)-PSA units (maximally 7 
residues). We conclude from these experiments that a-(2,8)- 
PSA units, which thus far in mammals have been found on only 
particular forms of NCAM, are also present on NCAM proteins 
in SCLC. H69 SCLC cells apparently contain both NCAM 
forms, one with the long a-(2,8)-PSA units at a high molecular 
weight range, and NCAM proteins with molecular weights of
145.000 and 185,000, which do not contain long a-(2,8)-PSA 
residues (Fig. 4A)>
DISCUSSION
Monoclonal antibodies 123C3 and 123A8 belong to a group 
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Fig. 4. Western blots of NKI-nbl-3 immunoprecipitates of H69 cells were 
immunostained with MAb NKI-nbl-3 (/Í), 735 (7?), and PBS (C). Immunoprecip- 
itates with (Lane 1) or without {Lane 2) neuraminidase treatment were kept at 
63 °C for 10 min before loading on the gel.
at various institutes throughout the world against SCLC cell 
lines, SCLC membrane preparations, or neuroblastomas. At a 
workshop in London in 1987, these antibodies were designated 
SCLC cluster 1 (6, 7). In this study we demonstrated that these 
SC-1 MAbs recognize the protein pattern of human NCAM. 
This finding is based upon similar reaction patterns in immu­
noinhibition, immunoprécipitation, and S. aureus V8 digestion 
studies between SC-1 MAbs and a reference polyclonal anti­
serum which recognizes NCAM (23). We have furthermore 
shown that all SC-1 MAbs studied, which were raised at differ­
ent institutes, recognize a restricted set of prominent epitopes 
on NCAM. All SC-1 MAbs studied fall into two groups, rec­
ognizing closely adjacent epitopes on NCAM. The first deter­
minant is recognized by MAb 123C3,123A8, NKI-nbl-3, NCC- 
LU-243, and MOC-32; the second determinant by NKI-nbl-1, 
NKI-nbl-2, NCC-LU-246, NE-25, NE-150, S-L 11-14, MOC- 
1, and MOC-21 (Table 2). Both groups of MAbs inhibited each 
other partially in their binding. This is probably due to steric 
hindrance and therefore suggests that these two antigenic de­
terminants are located close to each other on the same polypep­
tide. This cross-reactivity of SC-1 MAbs was confirmed by 
others at the First International Workshop on SCLC (21, 31, 
32).
NCAM is a sialoglycoprotein mediating intercellular adhe­
sion by homophilic binding to NCAM on another cell (15). 
Several NCAM protein isoforms are found on mouse and 
chicken neural cells, with molecular weights of 120,000,
140,000, and 180,000 (9). All forms are derived from a single 
copy gene by alternative mRNA splicing and/or posttransla- 
tional modifications (9, 33). A major modification is caused by 
a NCAM characteristic «-(2,8)-polysialyIation. Multiple a-
(2.8)-PSA units are attached to the NCAM isoforms at certain 
stages of embryonal development and in particular adult tissues
(9). This a-(2,8)-PSA-rich NCAM is recognized by Mab 735 
(24), which also detects the SC-1 antigens on SCLC cells (Fig. 
4). These results show that a-(2,8)-PSA-rich NCAM is present 
on SCLC.
In the case of the SCLC cell line H69, both forms of NCAM, 
the NCAM-H and -L forms, are present (Fig. 4). Fluorescence- 
activated cell sorter analysis with Mabs 123C3 and 735 showed 
that both NCAM forms were present on the same cells (data 
not shown). It is not yet clear whether the absence of long a-
(2.8)-PSA units in part of the SCLC-NCAM in H69 cells 
occurred as a result of tissue culture adaptation. The reverse, 
however, does not hold; SCLC cells do not acquire long a-(2,8)- 
PSA units under tissue culture conditions, since these are 
already present on SCLC tumor samples (34). We found im~ 
munoreactivity for antibodies recognizing NCAM in SCLC and 
some non-SCLC, which had a worse prognosis than negative 
non-SCLC (35).6 Whether expression of NCAM on human 
lung cancer cells results in a more invasive tumor behavior 
remains to be studied. In the human, NCAM is present on 
adult neural (36) and skeletal muscle cells (37). In tumors, 
NCAM expression has been described in Wilms1 tumor, neuro­
blastoma, and Ewing’s sarcoma (30, 38). NCAMs are expressed 
in a-(2,8)-PSA~rich NCAM forms in Wilms’ tumor, neuro­
blastoma, and, as described in this study, also in human SCLC.
One might speculate about the contribution of NCAM to the 
malignant behavior of tumor cells. For instance, the invasive 
behavior of these tumors could be attributed to the presence of 
a-(2,8)-PSA-rich NCAM forms. Polysialylation of NCAM dra­
matically reduces its adhesive capacity (16) and could therefore
R. E. Kibbelaar et a i manuscript in preparation.
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provoke invasive growth of tumor cells. Particular NCAM 
isoforms expressed in these tumor cells could also contribute 
to the malignant behavior of these cells. The SC-1 Mabs rec­
ognizing human NCAM now provide reagents to study a pos­
sible involvement of NCAM in the invasive behavior of SCLC.
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